Treats schizophrenia. ANDA 212923, held by Aurobindo Pharma. Clozapine.
As of Nov 15, 2026, ANDA 212923 (Clozapine), held by Aurobindo Pharma, was first approved by FDA on Dec 12, 2024, with 3 approved supplements and 0 published complete response letters.
Clozapine orally disintegrating tablets (Clozapine ODT) is an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine ODT should be used only in patients who have failed to respond adequately to standard antipsychotic treatment Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 12, 2024 | Original application | Approved | None posted |
| Clozapine12.5MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine25MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine100MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine150MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Clozapine200MG · tablet, orally disintegrating;oral | Clozapine | Rx |
| Jun 13, 2025 | Supplement 2REMS | Approved | None posted |
| Jun 13, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 9, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 12, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters